APA (7th ed.) Citation

Y, L., H, Y., QJ, Y., X, G., F, X., W, F., . . . HT, H. (2025). TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: A multicenter real-world study. Frontiers in oncology, 15, 1652319. https://doi.org/10.3389/fonc.2025.1652319

Chicago Style (17th ed.) Citation

Y, Li, et al. "TACE Combined with Regorafenib with or Without Anti-PD-1 Therapy for Advanced HCC After Targeted Therapy Failure: A Multicenter Real-world Study." Frontiers in Oncology 15 (2025): 1652319. https://doi.org/10.3389/fonc.2025.1652319.

MLA (9th ed.) Citation

Y, Li, et al. "TACE Combined with Regorafenib with or Without Anti-PD-1 Therapy for Advanced HCC After Targeted Therapy Failure: A Multicenter Real-world Study." Frontiers in Oncology, vol. 15, 2025, p. 1652319, https://doi.org/10.3389/fonc.2025.1652319.